Biocon Limited

Biocon Limited informed the BSE Limited and National Stock Exchange of India Limited that details of securities dematerialized during the quarter ended September 30, 2026, have been furnished to stock exchanges, as required under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, and confirmed by KFin Technologies Limited, the company’s Registrar and Share Transfer Agent, in a certificate dated October 7, 2026.

Biocon Ltd fell for a fifth straight session today. The stock is quoting at Rs 346.3, down 1.06% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 1.19% on the day, quoting at 22497.45. The Sensex is at 72444.21, up 1.19%.Biocon Ltd has eased around 11.58% in last one month.Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has eased around 2.39% in last one month and is currently quoting at 25823.25, up 0.38% on the day. The volume in the stock stood at 9.66 lakh shares today, compared to the daily average of 31.2 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 348.55, down 0.19% on the day. Biocon Ltd tumbled 2.02% in last one year as compared to a 11.03% slide in NIFTY and a 16.66% spurt in the Nifty Pharma index.The PE of the stock is 188.65 based on TTM earnings ending June 26.

Biocon Limited informed the Bombay Stock Exchange and National Stock Exchange of India that the trading window for dealing in the company's shares will be closed from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ending September 30, 2026.

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 394.4, up 2.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74818.76, up 0.71%. Biocon Ltd has dropped around 3.66% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 22.73 lakh shares today, compared to the daily average of 32.57 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 395.2, up 2.09% on the day. Biocon Ltd is up 8.91% in last one year as compared to a 7.1% drop in NIFTY and a 20.91% drop in the Nifty Pharma index.The PE of the stock is 208.11 based on TTM earnings ending June 26.

OneSource Specialty Pharma Ltd, Adani Ports & Special Economic Zone Ltd, Graphite India Ltd, DLF Ltd are among the other stocks to see a surge in volumes on BSE today, 09 September 2026.Biocon Ltd registered volume of 168.68 lakh shares by 10:48 IST on BSE, a 75.69 fold spurt over two-week average daily volume of 2.23 lakh shares. The stock rose 1.66% to Rs.399.05. Volumes stood at 1.22 lakh shares in the last session.OneSource Specialty Pharma Ltd clocked volume of 6.91 lakh shares by 10:48 IST on BSE, a 34.13 times surge over two-week average daily volume of 20246 shares. The stock lost 2.51% to Rs.1,546.35. Volumes stood at 86505 shares in the last session.Adani Ports & Special Economic Zone Ltd notched up volume of 60.33 lakh shares by 10:48 IST on BSE, a 21.53 fold spurt over two-week average daily volume of 2.80 lakh shares. The stock rose 2.53% to Rs.1,752.00. Volumes stood at 3.15 lakh shares in the last session.Graphite India Ltd notched up volume of 15.52 lakh shares by 10:48 IST on BSE, a 17.59 fold spurt over two-week average daily volume of 88204 shares. The stock rose 16.96% to Rs.859.00. Volumes stood at 56869 shares in the last session.DLF Ltd notched up volume of 33.55 lakh shares by 10:48 IST on BSE, a 15.06 fold spurt over two-week average daily volume of 2.23 lakh shares. The stock slipped 1.01% to Rs.669.15. Volumes stood at 9.14 lakh shares in the last session.

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while Nicholas Robert Haggar retired as an Independent Director. The company also appointed S.R. Batliboi & Associates LLP as its statutory auditors for a five-year term, replacing B S R & Co. LLP.

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while B S R & Co. LLP’s term as statutory auditors expired. S.R. Batliboi & Associates LLP was appointed as the new statutory auditors for a five-year term, concluding after the 53rd AGM in 2031, and Mr. Nicholas Robert Haggar retired as an Independent Director.

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while B S R & Co. LLP’s term as statutory auditors expired. S.R. Batliboi & Associates LLP was appointed as the new statutory auditors for a five-year term, concluding after the 53rd AGM in 2031, and Mr. Nicholas Robert Haggar retired as an Independent Director.

Biocon Ltd share price ticked higher by 0.51% to Rs 425.15. The Company's net profit plunged by 31.12% to Rs 136.8 crore, while revenue from operations eased by 4.29% to Rs 4291.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, rising 5.25%. It has improved by 0.41% over last one week and climbed by 11.45% in last one month while the market capitalization of Biocon Ltd has softened by 1.32% and 11.72% in the same period respectively. Profit before tax (PBT) of Biocon Ltd stood at Rs 127.6 crore in Q2 FY26, surging by 31.68% year-on-year, and nosediving by 48.44% quarter-on-quarter. EBITDA came in at Rs 793 crore, jumping 15.49% YoY and tumbling by 18.09% sequentially. Total expenses posted a minor rise of 0.66% to Rs 4036.2 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1424.1 crore, inching up 4.81% YoY, while employee benefits expense was at Rs 916.1 crore, ticking higher by 0.44% YoY. For the TTM ended FY26, revenue from operations rose 11.48% to Rs 16779.9 crore, while net profit tanked by 74.20% to Rs 368.8 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 222680% to Rs 3112.8 crore, and PBT collapsed by 76.26% to Rs 447.9 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1994.0 crore in FY26, as against Rs 4061.2 crore in FY25. Biocon Ltd jumped 11.16% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.

Biocon Limited announced the commercial launch of Yesafili™ (aflibercept), a biosimilar to Regeneron’s Eylea® 2 mg, in the United States, effective August 3, 2026. The product, which received U.S. Food and Drug Administration approval and interchangeable designation in May 2024, is indicated for the treatment of conditions such as age-related macular degeneration and diabetic macular edema, and is expected to benefit an estimated 19.8 million Americans.